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Abstract
Background/Aim: As continuous renal replacement therapy (CRRT) has emerged as a standard 
therapy in pediatric intensive care units (PICU), many related issues that may have an impact on 
circuit survival have gained in importance. Objective of the study was an evaluation of factors 
associated with circuit survival, including anticoagulation (ACG). Methods: Retrospective study 
that included 40 patients, who in total received 7636 hours of CRRT during 150 sessions (84 
filters, 4260 hours with heparin anticoagulation (Hep-ACG); 66 filters, 3376 hours with regional 
citrate anticoagulation (RCA)). Results: The Kaplan-Meier analysis of the total circuit survival 
time depending on the type of ACG did not demonstrate a significant difference between 
Hep-ACG and RCA. The percentage of clotted filters was significantly higher in case of smaller 
filters (HF20: 58.8%; ST60:29.5%; ST100: 15.8%), and their lifetime was significantly lower 
regardless of ACG (the mean and median lifetime for HF20: 38.7/27.0 h; for ST60: 54.1/72.0 
h., for ST100: 62.1/72.0 h, respectively). Conclusions: Irrespectively of filter size, filter clotting 
occurs within the first 24 hours after the initiation of CRRT. Most commonly, clotting affects 
small filters, and their lifetime is significantly shorter as compared to larger filters  regardless 
of the type of the ACG. 
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Introduction 
Owing to technical improvements over the past two decades, in many developed 
countries continuous renal replacement therapy (CRRT) has become the most preferred 
technique in managing critically ill children treated in pediatric intensive care units (PICUs) 
for acute kidney injury (AKI) and multi organ failure (MOF) [1].
As this technique has emerged as a standard, extracorporeal, supportive therapy, many 
CRRT-related issues that may potentially have an impact on the mortality in this patient 
population or on circuit survival have gained in importance [2]. One of these factors is the 
modality of the employed anticoagulation (ACG). Anticoagulation of the extracorporeal 
blood is necessary to maintain the patency of the circuit [3]. 
Currently, heparin anticoagulation (Hep-ACG), and regional citrate anticoagulation 
(RCA) remain the most commonly reported CRRT ACG methods in children. In recent years, 
Hep-ACG has been the most commonly used as the ACG modality [4]. Although heparin has 
the advantages of low cost, easy monitoring and simple reversal, it may increase the risk of 
life-threatening complications, such as bleeding or heparin-induced thrombocytopenia type 
II [5]. 
For a couple of years, RCA lacking systemic anticoagulation, which is an optimal option, 
especially in patients with a high bleeding risk [6, 7], offered an attractive alternative to Hep-
ACG [8, 9]. Although citrate is primarily used for extracorporeal anticoagulation, it also has 
an effect on energy supply, membrane-induced inflammation and indirectly on parathyroid 
hormone secretion. As citrate acts by chelating calcium and consequently inhibiting the 
clotting cascade, its infusion may lead to hypocalcemia, metabolic alkalosis and citrate 
toxicity [10].
 As the efficacy of CRRT therapies is directly related to the running time of the circuit 
and the most common complication is early clotting of the filter, hence it is important to use 
the best modality of ACG in those therapies. The ideal anticoagulant should act selectively 
in the circuit with minimal effects on patient homeostasis, be safe, available, consistently 
delivered, easily monitored, and reversible, and it should provide prolonged filter lifetime 
and high cost-effectiveness [11, 12]. 
 Despite considerable technological advances, there still remains space for significant 
improvement both in the patient outcomes and in the outcomes of circuit survival, as frequent 
circuit changes increase not only the nursing workload, blood loss and economic costs, but 
also compromise achievement of the filtration rate goals [13]. 
The main objective of the present study was an evaluation of the factors (comprising 
filter sizes and pressures characterizing the CRRT procedure) associated with circuit survival 
time, including the modality of the employed anticoagulation.
Material and Methods 
The present report describes an analytical, retrospective, single-center, chart-review study that 
included all 40 patients having been admitted to PICU in a tertiary pediatric center between January 2009 
and June 2016 and required CRRT. In total, the analyzed patients received 7636 hours of CRRT during 150 
CRRT sessions (on Hep-ACG: 84 filters, 4260 hours of CRRT, on RCA: 66 filters, 3376 hours of CRRT).  
 The investigation was approved by the local Bioethical Committee (L.Dz.OIL/KBL/4/2017). The 
detailed characteristics of the studied population is included in Table 1. 
A Prismaflex dialysis machine (Gambro, Spain) was used for CRRT in all patients. Dual lumen catheters 
between 7 F and 13 F were individually adapted to the child’s morphology and body weight according to 
literature recommendations, using the same criteria for patients treated with citrate (RCA) and heparin 
anticoagulation (Hep-ACG) [11, 14]. Hollow-fiber filters were used depending on the body weight of the 
patient according to the manufacturer’s guidelines [15]. 
In all Hep-ACG cases, the predilutional continuous venovenous hemodiafiltration was employed and 
unfractionated heparin was used. In the Hep-ACG protocol, a heparin bolus was administered during the 
connection along with a subsequent continuous heparin infusion to achieve a postfilter activated clotting 
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time (ACT) between 180 and 240 seconds. The ACT value was checked on average every 2 hours within the 
first 12 hours of CRRT and then every 4-6 hours. 
The RCA procedure was conducted according to the recommendations of Tolwani et al. [9, 16] 
and Prismaflex Operations Manual guidelines. An initial citrate concentration of 3.0 mmol/L was used 
for a target postfilter ionized calcium of 0.25 to 0.50 mmol/L. The citrate effect was neutralized using a 
continuous calcium infusion of 10% (or 5% in children weighting <15 kg) calcium gluconate to maintain 
ionized calcium blood levels between 0.9 and 1.2 mmol/L [15]. Samples were taken every hour for the first 
4 hours and every 6-8 hours afterwards. Total calcium levels were also checked at least once daily. Citrate 
accumulation was avoided by monitoring the patient’s pH status and maintaining the total calcium/ionic 
calcium index (CaT/CaI) at ≤ 2.5.
In case of the CRRT solutions, for Hep-ACG - Hemosol or PrismaSol 2 (Gambro) as dialysate and 
Phoxilium or PrismaSol 2 (Gambro) as predilutional substitute were used, whereas for RCA - citrate 
solution Prismocitrate 18/0 (Gambro) was administered on pre-blood pump (PBP), dialysate normo - 
carbonate solution PrismOcal B22 (Gambro) was used as calcium-free dialysis solution; and low-flow 
postfilter infusion of PrismaSol 2 (Gambro) or Phoxillum was employed as postdilutional substitute to avoid 
deaeration chamber for return line clotting.
In both techniques, dialysate and substitution flow rates were programmed initially to achieve the 
dialysis dose of at least 35 ml/kg/hour, and then were adjusted to the patient needs. None of the filters 
were used longer than 72 hours. Blood flow rates (BFR) were determined by the patient body weight and 
according by the accesses pressures [15].
The collected data pertained to the patients, vascular accesses, filter and circuit characteristics, as 
well as modality and dose of the employed anticoagulation. The parameters of the CRRT procedure (filter 
pressure, trans-membrane pressure - TMP, access pressure) were recorded every 2 hours. Due to a large 
number of native results (4200 results for each parameter) and considerable differentiation in the number 
of the results among individual filters, to meet the needs of further statistical analysis, a decision was made 
Table 1. Clinical characteristics of children treated with Hep-ACG and RCA. Pressors, diuretics and hypo-
tensive index medications were calculated by adding the number of days of drug administration in a given 
patient and dividing the resultant sum by the number of days of PICU hospitalization of the same patient
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to calculate the mean value for each filter, which was obtained following discarding the results with extreme 
values. The basic dose of CRRT was calculated daily, by average blood, dialysate, supplement and citrate (in 
case of RCA) flow rates. 
For ACT values, heparin doses, calcium compensation percent and citrate doses - all recorded values 
were included into the statistical analysis.
Prior to the study, 175 CRRT sessions were qualified. However, ultimately the analysis was performed 
for 150 filters selected when other than clotting causes of premature discontinuation of the procedure 
(patient decease -14, scheduled diagnostic or therapeutic procedures-11 cases) were excluded from the 
analysis, whereas cases of scheduled discontinuation of the procedure, when the patient ceased to require 
further treatment, continued to be included.
Statistical methods  
Particular groups of data were described by means of mean values, standard deviation (SD), median 
values and interquantile range (IQR). The comparison of data groups was performed by the t-Student test 
when the Gaussian distribution was confirmed by the Kolmogorov-Smirnov test (KS), with the threshold 
value assumed to be p>0.1 (pt). Otherwise, the Wilcoxon rank-sum test was employed (pW). The group 
sizes were compared using the chi-square test, where Yates correction was used for predicted frequencies 
below 5. To determine the predictive value and cut-off point for the selected parameters, the analysis of 
ROC curves was performed, arriving at the following values: Area Under ROC (AUROC), cut-off value based 
on the Youden index, sensitivity, specificity, Likelihood Ratio (LR), Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV). The effect of the selected parameters on the cumulative probability of filter 
survival was analyzed employing the Kaplan-Meier curves and the Mantel-Cox test, while Cox multivariable 
regression with determination of the Hazard Ratio (HR) was performed in comparing the effect of filter 
size and type of the applied anticoagulant upon filter lifetime. In all the tests with the exception of KS, the 
significance threshold was assumed as 0.05. The STATISTICA (version 12, StatSoft, Tulsa, OK, USA) and 
MATLAB (version 2015a, Mathworks, Natick, MA, USA) packages were used for all computations and to 
create the graphs.
Results 
As it follows from the data presented in Table 1, in total, the analysis was performed for 
7636 hours of CRRT, including 4260 hours of filter operation on Hep-ACG and 3376 hours of 
filter operation on RCA. In total, filter clotting occurred in 36% of the filters, including 29.8% 
Hep-ACG filters and 43.9% RCA filters. No significant difference was observed between the 
number of filters on Hep-ACG vs. RCA subpopulations, what indicates that the studied filter 
populations were mutually equivalent and representative. In the studied population, no 
difference was noted in mortality rates between the groups where Hep-ACG and the RCA 
was employed. Similarly, no differences were found in the majority of the analyzed clinical 
parameters describing the investigated patient population. The only significant difference 
involved the number of days at PICU (children treated employing the RCA method were 
hospitalized for a longer period) and the pressors and hypotensive medications indices. 
The number of hours of CRRT sessions employing HF20 filters was 1976, ST60: 3300, 
and ST100: 2360. Already at the stage of the preliminary analysis, it was demonstrated that 
in case of smaller filters, significantly higher dialysis doses were employed, higher blood 
flow rates were seen, while filter survival was significantly lower. The longest survival time 
was demonstrated by large filters (Table 2).
As it follows from the data presented in Table 3, clotted filters – regardless of their size 
- were characterized by higher filter pressure values, higher TMPs values and lower values 
of access pressure (what may be associated with a poorer quality of vascular access). On 
the other hand, no significant differences were noted in the parameters of the employed 
anticoagulation, both in the case of Hep-ACG and RCA, with the exception of HF20 filters, 
where a significantly higher heparin dose was noted at the beginning of the session (bolus), 
as well as a higher citrate dose in clotted filters and ST60 filters, where the mean ACT values 
were significantly higher in case of clotted filters. In case of the smallest filters, the circuits 
 Kidney Blood Press Res 2017;42:327-337
DOI: 10.1159/000477609
Published online: June 07, 2017
© 2017 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 331
Miklaszewska et al.: Survial of CRRT Circuits
employed in treating children with lower body mass were demonstrated to significantly more 
frequently be clotted. However, no differences were observed in dialysis doses between the 
groups of filters that were and were not clotted. The mean and median CaT/CaI ratio for RCA 
in the current study indicating citrate accumulation was 2.11 [SD:0.27]and 2.10 [IQR:0.28] 
mmol/l, respectively, which was within normal limits. 
As it follows from the analysis of the sole sub-population of 54 filters that were clotted, 
clotting most commonly affected small as compared to larger filters (HF20 vs. ST60: 
pt=0.001; HF20 vs. ST100: pW=0.018); while there were no significant differences in clotting 
frequency between ST60 vs. ST100 filters; no difference was also noted in the time needed 
by particular filters to become clotted. The significantly longest ACT time was maintained 
in case of ST60 filters (ST60 vs. HF20: pt=0.032 and ST60 vs. ST100: pt=0.041). On the 
other hand, the highest doses of heparin administered at the beginning of the procedure 
as boluses per one kilogram of body mass were given to the smallest children (HF20 vs. 
ST100: pW=0.016; HF20 vs. ST100: pW=0.015; ST60 vs. ST100: pW=0.005). In case of RCA, 
no significant differences were noted between clotted filters in ACG parameters. 
Data presented in Table 4 and Fig. 1 indicate that no significant differences were noted 
in the total filter running time depending on the type of the ACG employed. Citrate flow in 
the RCA technique – in case of HF20 filters – was associated with a higher dose of dialysis 
supplied and a significantly higher TMP, but the differences did not affect the survival time 
of the circuits. In case of HF20 and ST60 filters, RCA was selected for patients with higher 
body mass. 
Table 2. General characteristics of all the studied filters. The variables are described as mean values [SD]/
median values [IQR].(P1: HF20 vs. ST60; P2: HF20 vs. ST100; P3: ST60 vs. ST100), BFR - blood fow rate
Table 3. Detailed filter characteristics: 1 - CRRT session discontinuation due to filter clotting; 2-scheduled 
CRRT session discontinuation. The variables are presented as mean values [SD]/median values [IQR]. Neg-
ative access pressure is described in the table by an absolute value, TMP - trans membrane pressure, BFR 
- blood flow rate
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p=0.004; HR=11.2, p=0.022). Thus, after 36 hours of the circuit operation, the probability of 
clotting of RCA filters became more than 11-fold higher as compared to Hep-ACG filters. But 
when the filters were divided into groups according to their size, no differences were noted 
in survival time between the compared ACG methods, what indicates that differences in filter 
survival time depend on filter size rather than the employed ACG method. 
Irrespectively of the type of ACG employed, significant differences were demonstrated 
in each case in the percentage of filter survival when comparing HF20 vs. ST100 filters. 
A comparison of survival percentage between HF20 vs. ST60 filters showed significant 
differences for all the three time points in all the filters, while in the case of Hep-ACG, a 
significantly lower number of HF20 filters survived 48 and 60 hours, and in case of RCA - 60 
and 72 hours of the circuit operation. Differences in percentage of survival between ST60 vs. 
ST100 filters were non-significant, with the exception of 72 hours in the analysis involving 
all the filters (Table 5).
The data included in Table 6 confirm the absence of a difference in the percentage of 
filter clotting depending on their size within a given ACG method, with the exception of a 
Fig. 1. Kaplan-Meier circuit lifetime survival analysis (n=150). The survival 
curves were compared with the Mantel-Cox test (NS).
Table 4. CRRT parameters depending on the employed ACG modality. The variables are presented as mean 
values [SD]/median values [IQR], BFR - blood flow rate
While assessing 
the Kaplan-Meier 
survival curves plotted 
for the 150 filters for 
the observation time 
of 0 to 72 hours and 
for the observation 
time of 0 to 36 hours 
(including the 36-th 
hour), no significant 
difference was noted 
in filter survival values 
depending on the 
ACG employed. On the 
other hand, for the 
observation time of after 
36 to 72 hours of filter 
operation, there was 
detected a significant 
difference in filter 
survival time in favor 
of filters with Hep-ACG 
(the Mantel-Cox test: 
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significant difference for RCA 
between HF20 vs. ST100. No 
differences were also noted 
either in the percentage of 
filter survival or in the time of 
their operation as depending 
on the employed ACG 
modality within particular 
filter size groups. On the 
other hand, smaller filters 
were demonstrated to operate 
shorter as compared to larger 
filters employed within the 
same type of ACG. 
The process of data 
analysis also included Cox 
multivariable regression 
addressing filter survival (the 
analysis was performed at 12 
hours), which showed that in 
no case was the type of the 
employed ACG of importance 
with respect to its affecting 
filter survival time. On the 
other hand, filter size proved 
to be of significance. When 
a comparison was made 
between HF20 vs. ST60, the 
risk of clotting increased 2.36-
fold every 12 hours (95%CI: 
1.21-4.61; p=0.012), while 
when comparing HF20 vs. 
ST100, the said risk increased 
5.64-fold (95%CI: 2.65-14.06; 
p=0.000).
Table 7 presents data 
on the values of selected 
parameters describing filter 
pressure in particular types 
of filters. From these data, 
the values of cut-off points for 
filter pressure can be inferred, 
together with the value of the 
likelihood ratio, which shows 
how many times the risk of 
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filter clotting is increased as compared to a filter that will not 
clot, with the test predictive value being good or very good 
(presented AUROCs values were at least 80%).  In view of 
the fact that in case of ST100 filters, only one RCA filter was 
clotted, calculation of the AUROCs value was not possible. 
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Discussion 
Prolonged circuit survival is very important, as early filter clotting may have several 
negative effects, including a decreased efficacy of treatment, increased blood loss, 
hemodynamic instability and increased costs [12]. On the other hand, the circuit life span 
is affected by many factors, such as the patient’s clinical condition, coagulation status, the 
position and patency of the vascular access, the choice of anticoagulant, the modality of 
CRRT and filtration fraction [17].
In the studied population, there were no cases of severe side effects associated with the 
applied modality of ACG. Treatment was generally well tolerated in all the patients, and the 
flow rate adaptability to the patient needs was highly acceptable.
The principal objective of the study was the assessment of factors affecting filter 
survival and the supplied dialysis dose depending on the employed anticoagulation method. 
In the current literature, there are divergent results about the superiority of the applied 
modality of ACG (Hep-ACG vs. RCA) in terms of circuit survival [12]. There are randomized 
and observational studies proving that RCA significantly extends CRRT circuit lifetime as 
compared to heparin [11-13, 18] and studies showing no significant differences between 
those two modalities of ACG [19, 20].
Unfractionated heparin - due to its pharmacokinetics and reversibility - has been widely 
used for CRRT ACG for decades [14]. According to the literature, heparin is an effective ACG 
in CRRT therapy with a mean dose of 11.1-20 U/kg/h and a post-filter ACT being maintained 
between 180 and 240 sec. [11, 19]. The heparin doses employed in the present study were 
similar to the values reported in the literature [19] and did not affect the percentage of filter 
clotting, regardless of their size. With the exception of ST60 filters, no significant differences 
were observed in the ACT time in clotted and non-clotted filters (Table 3). 
In the study on RCA by Fernández et al., the median citrate dose was 2.6 mmol/l, the 
median and maximum CaT/CaI index was 2.16 and 2.33, respectively [11]. In the present 
report, the mean values of citrate doses were higher than in the cited study and there were 
no significant differences between the filter types (Table 3). The CaT/CaI ratio was within 
normal limits. According to the literature, RCA is not only a safe and effective ACG modality 
for pediatric CRRT, but it also achieves longer circuit survivals than Hep-ACG; hence, the 
use of RCA may provide a substantial cost saving and it is an ideal option in a critically ill 
children after recent surgery or with coagulopathy, for whom systemic ACG is discouraged 
[11]. Supporting this conclusion in their study, Sołtysiak et al. [21] stated that the circuit 
lifetime was significantly higher in RCA than in Hep-ACG (58.04 h vs. 37.64 h) and early circuit 
clotting was observed in 11.63% of children receiving RCA and 34.15% of those receiving 
Hep-ACG. Similarly, in a study by Fernández et al. [11], the median RCA circuit survival was 
48 hours, while in case of Hep-ACG - 31 hours and the difference was statistically significant. 
Nevertheless, in both the aforementioned studies, the authors considered all the studied 
filter types as a single homogenous group (HF20, ST60 filters [21], and HF20, ST60, ST100 
filters [11]). However, in the study by Rico et al. [22], the authors not only proved that the 
Table 7. Prog-
nostic capacity 
of mean ROCs 
values for se-
lected filters 
(mmHg), for 
circuit clotting 
depending on 
the applied ACG 
modality; AUROC - area under the receiver operating characteristic curve; LR -likelihood ratio; PPV -positive 
predictive value; NPV - negative predictive value
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survival of filters was higher in the RCA (72 h) than in the Hep-ACG (18 h) group, but they 
also showed that the filter coagulation risk was significantly increased when heparin was 
used, regardless of filter size. 
In the current literature, there are also contrary results that state that the mean circuit 
survival is no different between HepACG and RCA [19, 23]. In a study by Brophy et al. [19], 
the clotting rates were similar for Hep-ACG circuits (25%) and RCA circuits (27%) and the 
analysis showed that 69% of Hep-ACG and Cit-ACG circuits were functional at 60 hours. 
Contrary to some of the above quoted studies ([11, 19, 21]), in the present report the 
investigated filters were divided according to their size and all the statistical analyses (Tables: 
2-7) addressed a given filter size, what represents a fairly novel approach to the problem. 
Thanks to such a view, it was demonstrated that filter survival was significantly affected by 
its size rather than the type of ACG employed (Tables: 2,3,5). Anyhow, according to Rico et al. 
[22], filter size is irrelevant to filter survival time, but yet the authors only evaluated filters 
of 0.4 and 0.7 m2 of size. In the current paper, a wider range of filter sizes including HF20 
(0.2m2), ST60 (0.6 m2) and ST100 (0.9 m2) were analyzed, which allowed for demonstrating 
the impact of a very small size of the filter (HF20) on circuits survival.  
On the average, the filters underwent clotting between 21.2 and 23.8 hours of their 
operation and no significant differences were observed between particular filter types 
(Table 3). While evaluating filter survival time depending on the type of the employed ACG 
modality, no significant difference was demonstrated between Hep-ACG and RCA (Table: 4, 
6). Only in the Kaplan-Meier analysis, when the time span exceeding 36 hours was taken 
into consideration, was the probability of the RCA filter clotting more than 11-fold higher as 
compared to the Hep-ACG filter (Fig.1). Nevertheless, in the same analysis, when the filters 
were divided according to their size, no differences were demonstrated in the survival time 
between the analyzed ACG modalities, what indicates that differences in filter survival time 
depend on their size rather than the employed ACG method. 
The data examination also included Cox multivariable regression addressing filter 
survival, which also demonstrated that in none of the cases, the type of the employed ACG 
modality was of importance in the effect of filter survival time, while filter size turned 
out to be of significance. For HF20 filters, the risk of clotting increased more than twofold 
every 12 hours as compared to ST60 filters, and more than five-fold as compared to ST100 
filters. Additionally, in the present paper, calculations were made of the cut-off points for 
the parameter of filter pressure for particular types of filters, achieving a good or very good 
predictive value of the test (Table  7). 
Determining the optimal therapeutic dose for CRRT in critically ill children remains 
a challenge. CRRT doses should be determined according to the disease conditions, taking 
into consideration the metabolic state, fluid volume, and duration of dialysis [24]. Here, the 
employed ACG modality also exerts a significant impact. According to the current literature, 
the total mean dialysis dose and mean blood flow rate in children are 52 ml/kg/h [21] and 
5.2 ml/kg/min [25], respectively. In a study by Fernández et al. [11], although the total 
CRRT dose was higher in the RCA as compared to the Hep-ACG group, the difference was 
not statistically significant (69 vs. 59 ml/kg/h). The present study demonstrated that in the 
case of the smallest filters (and thus in the youngest children), significantly higher dialysis 
doses were employed, as well as significantly higher blood flow rate values (Table 2). On the 
other hand, no differences were shown between clotted and non-clotted filters with respect 
to the prescribed dialysis dose (Table 3), although a significantly higher dialysis dose was 
noted in the population of HF20 filters in the RCA group as compared to ACG-Hep, what is 
associated with an additional citrate flow (Table  4). Attention was also drawn to significantly 
higher heparin doses administered at the beginning of the procedure as boluses given to the 
youngest children.
The authors are aware of the limitations of the present retrospective, single-center, 
observational study, with only 8 patients being treated with RCA. Nevertheless, no significant 
difference was observed between the number in the two analyzed filter populations (Hep-
ACG vs. RCA), what indicates their being mutually equivalent; furthermore the study resulted 
from a detailed analysis of 7636 hours of operation of 150 filters, taking into consideration all 
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their most important parameters, including the percentage of clotted filters, time of circuit 
operation, filter pressure values, TMP values, parameters of heparin and citrate ACG and 
the dose of the supplied dialysis, and employing a novel approach consisting in dividing the 
filters into particular size-associated types. Moreover, the authors calculated cut-off points 
for filter pressure values, at which – when exceeded – the risk of circuit clotting is increased. 
In the opinion of the authors, having such data at one’s disposal in clinical practice may 
prove to be highly helpful in monitoring CRRT procedures and in more active preventing 
circuit clotting, what should be reflected not only in higher efficacy and safety of the method, 
but also in its economic aspect. 
Conclusions 
In the present study, no significant difference was noted in filter survival time depending 
on the type of the employed anticoagulation; only when time interval beyond 36 hours was 
taken into consideration, the authors did demonstrate that the risk of RCA filter clotting 
was more than 11-fold higher as compared to Hep-ACG filters. Filter clotting, irrespectively 
of their size, most often occurs in the first 24 hours following CRRT initiation. Clotting the 
most frequently involves small filters (HF20), and the time of their operation is significantly 
shorter as compared to larger filters (ST60, ST100), irrespectively of the type of ACG 
employed. In case of HF20 filters, the risk of clotting increases more than two fold every 12 
hours as compared to ST60 filters and more than five-fold as compared to ST100 filters.
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